QQ客服 官方微博 反馈留言

	Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial
	Li Jian-Wei[1]; Liu Guang-Yu[2]; Ji Ya-Jie[3]; Yan Xia[4]; Pang Da[5]; Jiang Ze-Fei[6]; Chen De-Dian[7]; Zhang Bin[8]; Xu Bing-He[9]; Shao Zhi-Ming[10]
刊名	Cancer management and research
	2019
卷号	11页码:299-307
关键词	GnRH analogs adjuvant therapy anastrozole aromatase inhibitors breast cancer tamoxifen
ISSN号	1179-1322
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/2164041
专题	上海大学
作者单位	1.[1]Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China, zhimingshao@fudan.edu.cn. 2.[2]Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China, zhimingshao@fudan.edu.cn. 3.[3]Department of Breast Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China. 4.[4]Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China, zhimingshao@fudan.edu.cn. 5.[5]Department of Breast Surgery, The Third Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China. 6.[6]Department of Oncology, 307 Hospital of People's Liberation Army, Beijing, People's Republic of China. 7.[7]Department of Breast Diseases, Cancer Hospital of Yunnan Province, Kunming, People's Republic of China. 8.[8]Department of Breast Surgery, Cancer Hospital of Liaoning Province, Shenyang, People's Republic of China. 9.[9]Department of Oncology, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, People's Republic of China. 10.[10]Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China, zhimingshao@fudan.edu.cn.
推荐引用方式 GB/T 7714	Li Jian-Wei[1],Liu Guang-Yu[2],Ji Ya-Jie[3],et al. Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial[J]. Cancer management and research,2019,11:299-307.
APA	Li Jian-Wei[1].,Liu Guang-Yu[2].,Ji Ya-Jie[3].,Yan Xia[4].,Pang Da[5].,...&Shao Zhi-Ming[10].(2019).Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial.Cancer management and research,11,299-307.
MLA	Li Jian-Wei[1],et al."Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial".Cancer management and research 11(2019):299-307.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。